90473-01-1

Usage

Uses

Used in Pharmaceutical Industry:
(+)-(1R,2R,5R)--Ethyl [(2-Hydroxypinan-3-ylene)aMino]acetate is used as an intermediate in the synthesis of D-erythro-Sphingosine (S681000) for its potential therapeutic applications. D-erythro-Sphingosine has been studied for its role in cell signaling and membrane stability, making it a promising candidate for the development of drugs targeting various diseases.
Used in Chemical Synthesis:
(+)-(1R,2R,5R)--Ethyl [(2-Hydroxypinan-3-ylene)aMino]acetate is used as a chiral building block in the synthesis of other complex organic compounds. Its unique stereochemistry allows for the creation of enantiomerically pure products, which is crucial in many chemical and pharmaceutical applications where the stereochemistry of a molecule can significantly impact its biological activity.
Used in Research and Development:
(+)-(1R,2R,5R)--Ethyl [(2-Hydroxypinan-3-ylene)aMino]acetate is utilized in research settings to study the effects of stereochemistry on the properties and reactivity of molecules. Its clear liquid form and distinct chemical properties make it an ideal candidate for investigations into asymmetric synthesis, chiral recognition, and the development of new methodologies for the preparation of enantiomerically pure compounds.

Upstream product

• 7785-26-4 (-)-α-pinene 
• 22422-34-0 (1R,2R,3S,5R)-2,3-pinane diol 
• 623-33-6 glycine ethyl ester hydrochloride 
• 1845-25-6 (-)-(2R,3R,5R)-2-hydroxy-3-pinanone 
• 459-73-4 GlyOEt*HCl 

Downstream Products

• 92812-82-3 6-<(18)F>fluoro-L-DOPA 
• 1319734-54-7 C₂₁H₃₅NO₅ 
• 1319734-53-6 C₂₁H₃₅NO₅ 
• 35597-44-5 L-phosphinothricin 
• 73679-07-9 (S)-(+)-phosphinothricin 

Relevant academic research and scientific papers

NOVEL SYNTHESIS INTERMEDIATES FOR OBTAINING DERIVATIVES OF SPHINGOSINES, CERAMIDES AND SPHINGOMYELINS WITH GOOD YIELDS

The subject matter of the present invention is the novel molecules of formulae E, E′ and F. These molecules prove to be synthesis intermediates that are very advantageous for the manufacture of derivatives of sphingosine or of ceramides functionalized in position 1, with good yields, in which R1 and R2 are fatty chains, R3 is an alkyl group and R4 is a protective group for alcohol functions. Another subject of the invention is the use of the intermediates of type F for converting same into intermediates of type G, by means of reduction in the presence of lithium borohydride. The G molecules are precursors that are known to make it possible to obtain sphingolipids or sphingomyelin.

ALPHA-GALACTOSYLCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The invention relates to α-galactoceramide analogs, their methods of manufacture, intermediate compounds useful in these methods. It also relates to pharmaceutical compositions containing the α-galactoceramide analogs. The methods of manufacture of the invention involve the use of unsaturated intermediate compounds which enable to synthesize α-galactoceramide analogs by a mere metathesis reaction. The α-galactoceramide analogs of the invention are useful as active ingredients of pharmaceutical compositions, particularly in pharmaceutical compositions having anti-cancerous properties.

A four-step synthesis of erythro-m-chloro-3-hydroxytyrosine ethyl ester enantiomerically pure

Pure erythro-m-chloro-3-hydroxytyrosine having the (2R,3R) configuration, a residue of Vancomycin and Aridicin A, has been prepared in 4 steps using an aldol addition involving a directly generated titanium enolate derived from a chiral iminoglycinate. (+)-Hydroxypinanone was used as a recoverable chiral auxiliary. The (2S,3S)-erythro isomer will be, of course, available from (-)-hydroxypinanone.

ASYMMETRIC SYNTHESIS OF (+)-PHOSPHINOTHRICIN and (+)-2-AMINO-4-PHOSPHONOBUTYRIC ACID

Asymmetric synthesis of (+)-phosphinothricin, (+)-2-amino-4-phosphono-butyric acid, and their enantiomers has been achieved by the Michael addition of chiral glycine Schiff bases to vinyl phosphorus compounds.